ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1452

Combination of Ultrasound Power Doppler-Verified Synovitis and Seropositivity Accurately Identifies Patients with Early Rheumatoid Arthritis

Shinya Kawashiri1, Keita Fujikawa2, Ayako Nishino1, Ayuko Takatani1, Toshimasa Shimizu1, Masataka Umeda1, Shoichi Fukui1, Takashi Igawa1, Tomohiro Koga1, Naoki Iwamoto1, Kunihiro Ichinose1, Mami Tamai1, Hideki Nakamura1, Tomoki Origuchi3 and Atsushi Kawakami1, 1Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Japan Community Health care Organization Isahaya General Hospital, Nagasaki, Japan, 3Department of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: anti-CCP antibodies, diagnosis, rheumatoid arthritis (RA) and ultrasonography, Rheumatoid Factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: We conducted this retrospective study to determine objective and comprehensive diagnostic criteria for early rheumatoid arthritis (RA) that are based on ultrasound (US) and serologic findings.

Methods: From August 2014 to May 2016, we recruited 216 consecutive patients at Hospital 1 and 223 consecutive patients at Hospital 2 who were suspected to have RA and underwent US of bilateral hands. The duration from the appearance of the patient’s symptoms to his or her entry into the study was ≤6 months. In the US of bilateral hands from 22 sites, the findings obtained by grayscale (GS) and power Doppler (PD) assessments were graded on a semi-quantitative scale from 0 to 3. We also examined the assessment of the novel Outcome Measures in Rheumatology (OMERACT)-European League Against Rheumatism (EULAR) combined power Doppler ultrasound (PDUS) score (i.e., the cPD score) and the Global OMERACT-EULAR Synovitis Score (GLOESS). The diagnostic performance of the patients was evaluated using US findings and the combination of US and serologic findings.

Results: Seventy patients (32.4%) at Hospital 1 and 59 patients (26.5%) at Hospital 2 were diagnosed as having RA. The best-balanced diagnostic performance at each hospital was achieved using a combination, such as (1) the presence of PD grade ≥2 articular synovitis or (2) the presence of PD grade ≥1 articular synovitis and serologic positivity, as well as (1) the presence of cPD grade = 3 or (2) a cPD grade ≥2 and serologic positivity (Table 1 and 2).

Conclusion: The combination of a PD assessment or the cPD score with the measurement of autoantibodies of rheumatoid factor and/or anti-cyclic citrullinated peptide antibodies can accurately identify the patients with early RA.

Table 1. Diagnostic performance of RA classification criteria, and serologic and ultrasound findings

 

Hospital 1

Hospital 2

Sensitivity

Specificity

PPV

NPV

Accuracy

Sensitivity

Specificity

PPV

NPV

Accuracy

2010 ACR/EULAR criteria

71.4

84.9

69.4

86.1

80.6

57.6

93.3

75.6

86.0

83.9

Seropositivity

RF-positive

75.7

78.1

62.4

87.0

77.3

74.6

73.1

50.0

88.9

73.5

ACPA-positive

64.3

90.4

76.3

84.1

81.9

67.8

92.1

75.5

88.8

85.7

RF- and/or ACPA-positive

77.1

73.3

58.1

87.0

74.5

78.0

70.7

48.9

89.9

72.3

US findings

 

 

 

 

 

 

 

Articular synovitis

 

 

 

 

 

 

 

Synovial hypertrophy:

 

 

 

 

 

 

 

GS grade ≥1*

98.6

31.5

40.8

97.8

53.2

89.8

62.8

46.5

94.5

70.0

GS grade ≥2*

85.7

85.6

74.1

92.6

85.6

79.7

79.9

58.8

91.6

79.8

GS grade 3*

44.3

97.9

91.2

78.6

80.6

5.1

98.8

60.0

74.3

74

Vascularity:

 

 

 

 

 

 

 

PD grade ≥1*

91.4

86.3

76.2

95.5

88.0

86.4

78.0

58.6

94.1

80.2

PD grade ≥2*

84.3

95.2

89.4

92.7

91.7

67.8

94.5

81.6

89.1

87.4

PD grade 3*

17.1

99.3

92.3

71.4

72.7

3.4

99.4

66.7

74.1

74.0

Total PD score ≥2

88.6

90.4

81.6

94.3

89.8

79.7

90.9

75.8

92.5

87.9

OMERACT-EULAR combined scoring system:

 

 

 

 

 

 

 

 

 

 

cPD grade ≥1*

98.6

31.5

40.8

97.8

53.2

89.8

62.8

46.5

94.5

70.0

cPD grade ≥2*

90.0

86.3

75.9

94.7

87.5

81.4

79.9

59.3

92.3

80.3

cPD grade 3*

51.4

97.9

92.3

80.8

82.9

8.5

98.1

62.5

74.9

74.4

Total cPD score ≥3

94.3

62.3

54.5

95.8

72.7

NT

NT

NT

NT

NT

GLOESS ≥2

78.6

68.5

54.5

87.0

71.8

NT

NT

NT

NT

NT

*Presence of at least one joint or tendon. ACPA, anti-cyclic citrullinated peptide antibody; ACR, American College of Rheumatology; cPD, combined power Doppler; EULAR, European League Against Rheumatism; GLOESS, Global OMERACT-EULAR Synovitis Score; GS, grayscale; NPV, negative predictive value; PD, power Doppler; PPV, positive predictive value; RA, rheumatoid arthritis; RF, rheumatoid factor; NT, not tested.

 

Table 2. Diagnostic performance of combination of ultrasound and serologic findings

 

Hospital 1

Hospital 2

Sensitivity

Specificity

PPV

NPV

Accuracy

Sensitivity

Specificity

PPV

NPV

Accuracy

GS grade ≥2 and PD grade ≥1*

84.3

91.1

81.9

92.4

88.9

78

86.6

67.6

91.6

84.3

GS grade ≥2 or PD grade ≥1*

92.9

82.9

72.2

96.0

86.1

88.1

71.3

52.5

94.4

75.8

(1) PD grade ≥2* or

(2) GS grade ≥2 + PD grade ≥1*

88.6

91.1

82.7

94.3

90.3

80

86.6

68.1

92.2

84.8

(1) PD grade ≥2* or

(2) PD-positive tenosynovitis*

88.6

93.2

86.1

94.4

91.7

81.4

78.7

57.8

92.1

79.4

(1) PD grade ≥1* and (2) RF/ACPA-positive

70

97.3

92.5

87.1

88.4

64.4

97

88.4

88.3

88.3

(1) PD grade ≥2* and (2) RF/ACPA-positive

62.9

100

100

84.9

88.0

50.8

99.4

96.8

84.9

86.5

(1) PD grade ≥2*or

(2) PD grade ≥1* and RF/ACPA-positive

91.4

92.5

85.3

95.7

92.1

81.4

92.1

78.8

93.2

89.2

(1) cPD grade ≥1* and (2) RF/ACPA-positive

75.7

77.4

61.6

86.9

76.9

67.8

89.6

70.2

88.6

83.9

(1) cPD grade ≥2* and (2) RF/ACPA-positive

68.6

97.9

94.1

86.7

88.4

59.3

95.7

83.3

86.7

86.1

(1) cPD grade ≥2*or

(2) cPD grade ≥1* and RF/ACPA-positive

97.1

67.8

59.1

98.0

77.3

91.5

73.8

55.7

96.0

78.5

(1) cPD grade =3*or

(2) cPD grade ≥2* and RF/ACPA-positive

85.7

95.6

90.9

93.3

92.6

66.1

93.9

79.6

88.5

86.5

*Presence at least one joint or tendon. ACPA, anti-cyclic citrullinated peptide antibody; cPD, combined power Doppler; GS, grayscale; NPV, negative predictive value; PD, power Doppler; PPV, positive predictive value; RA, rheumatoid arthritis; RF, rheumatoid factor.

 


Disclosure: S. Kawashiri, None; K. Fujikawa, None; A. Nishino, None; A. Takatani, None; T. Shimizu, None; M. Umeda, None; S. Fukui, None; T. Igawa, None; T. Koga, None; N. Iwamoto, None; K. Ichinose, None; M. Tamai, None; H. Nakamura, None; T. Origuchi, None; A. Kawakami, None.

To cite this abstract in AMA style:

Kawashiri S, Fujikawa K, Nishino A, Takatani A, Shimizu T, Umeda M, Fukui S, Igawa T, Koga T, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Kawakami A. Combination of Ultrasound Power Doppler-Verified Synovitis and Seropositivity Accurately Identifies Patients with Early Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/combination-of-ultrasound-power-doppler-verified-synovitis-and-seropositivity-accurately-identifies-patients-with-early-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/combination-of-ultrasound-power-doppler-verified-synovitis-and-seropositivity-accurately-identifies-patients-with-early-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology